A
Alba A. Brandes
Researcher at Academy for Urban School Leadership
Publications - 377
Citations - 47155
Alba A. Brandes is an academic researcher from Academy for Urban School Leadership. The author has contributed to research in topics: Temozolomide & Bevacizumab. The author has an hindex of 70, co-authored 360 publications receiving 39954 citations. Previous affiliations of Alba A. Brandes include Vita-Salute San Raffaele University & European Organisation for Research and Treatment of Cancer.
Papers
More filters
Journal ArticleDOI
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
TL;DR: The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.
Journal ArticleDOI
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp,Monika E. Hegi,Warren P. Mason,Martin J. van den Bent,Martin J.B. Taphoorn,Robert C. Janzer,Samuel K. Ludwin,Anouk Allgeier,Barbara Fisher,Karl Belanger,Peter Hau,Alba A. Brandes,J.M.M. Gijtenbeek,Christine Marosi,Charles J. Vecht,Karima Mokhtari,Pieter Wesseling,Salvador Villà,Elizabeth Eisenhauer,Thierry Gorlia,Michael Weller,Denis Lacombe,J. Gregory Cairncross,René-Olivier Mirimanoff +23 more
TL;DR: Benefits of adjuvant temozolomide with radiotherapy lasted throughout 5 years of follow-up, and a benefit of combined therapy was recorded in all clinical prognostic subgroups, including patients aged 60-70 years.
Journal ArticleDOI
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Olivier Chinot,Wolfgang Wick,Warren P. Mason,Roger Henriksson,Frank Saran,Ryo Nishikawa,Antoine F. Carpentier,Khê Hoang-Xuan,Petr Kavan,Dana Cernea,Alba A. Brandes,Magalie Hilton,Lauren E. Abrey,Timothy F. Cloughesy +13 more
TL;DR: The addition of bevacizumab to radiotherapy-temozolomide did not improve survival in patients with glioblastoma, and the glucocorticoid requirement was lower.
Journal ArticleDOI
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
Martin J. van den Bent,Alba A. Brandes,Martin J.B. Taphoorn,Johan M. Kros,Mathilde C.M. Kouwenhoven,Jean-Yves Delattre,Hans J.J.A. Bernsen,Marc Frenay,Cees C. Tijssen,Wolfgang Grisold,László Sipos,Roelien H. Enting,Pim J. French,Winand N.M. Dinjens,Charles J. Vecht,Anouk Allgeier,Denis Lacombe,Thierry Gorlia,Khê Hoang-Xuan +18 more
TL;DR: The addition of six cycles of PCV after 59.4 Gy of RT increases both OS and PFS in anaplastic oligodendroglial tumors, and 1p/19q-codeleted tumors derive more benefit from adjuvant PCV compared with non-1p/ 19q-deleted tumors.
Journal ArticleDOI
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp,Roger Stupp,Monika E. Hegi,Thierry Gorlia,Sara Erridge,James Perry,Yong-Kil Hong,Kenneth Aldape,Benoit Lhermitte,Torsten Pietsch,Danica Grujicic,Joachim P. Steinbach,Wolfgang Wick,Rafal Tarnawski,Do-Hyun Nam,Peter Hau,Astrid Weyerbrock,Martin J B Taphoorn,Chiung-Chyi Shen,Nalini Rao,László Thurzó,Ulrich Herrlinger,Tejpal Gupta,Rolf-Dieter Kortmann,Krystyna Adamska,Catherine McBain,Alba A. Brandes,Joerg C. Tonn,Oliver Schnell,Thomas Wiegel,Chae-Yong Kim,Louis B. Nabors,David A. Reardon,Martin J. van den Bent,Christine Hicking,Andriy Markivskyy,Martin Picard,Michael Weller +37 more
TL;DR: This multicentre, open-label, phase 3 study investigated the efficacy of cilengitide in patients from 146 study sites in 25 countries and found none of the predefined clinical subgroups showed a benefit.